Autres langues Mauna Kea Technologies

Actions

ALMKT

FR0010609263

Temps réel Euronext Paris Autres places de cotation 11:13:02 30/04/2024			Varia. 5j.	Varia. 1 janv.
0,392 ^EUR	+1,03 %		+3,70 %	-16,77 %

09:02	Après Microsoft, Alphabet, Tesla et Apple, Amazon doit faire le job
08:42	En Direct des Marchés : Thales, Stellantis, Capgemini, Atos, VusionGroup, Orpea, Adidas, HSBC...

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics	29/04
Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	29/04
Mauna Kea Technologies : Inside Information / Information on annual revenues	25/04
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales	25/04
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024	25/04
Mauna Kea Technologies : Reports Full Year 2023 Results and Q1 2024 Sales	25/04
Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank	24/04
Mauna Kea : premier centre italien pour Cellvizio	03/04
Bolsa de Madrid: Después de Semana Santa, algo va mal	03/04
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	02/04
Mauna Kea Technologies : Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	02/04
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	27/03
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	27/03
Mauna Kea : partenariat avec Metrodora Institute aux USA	06/03
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	06/03
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	06/03
MAUNA KEA TECHNOLOGIES REPORTS FULL YEAR 2023 SALES OF EUR10.5M, UP +42% VS 2022	26/01
Mauna Kea : Johnson & Johnson Innovation sous les 20%	24/11
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals	13/11
Mauna Kea : le titre bondit, Telix prend 19% du capital	13/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mauna Kea Technologies

Actions

ALMKT

FR0010609263

Autres langues

Filtres